CANCER ADVANCES INC.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

An Open Label Study to Evaluate G17DT Compared to Gemcitabine

Phase 3
Completed
Conditions
Pancreatic Cancer
Interventions
Biological: G17DT
Drug: Gemcitabine
First Posted Date
2017-06-27
Last Posted Date
2017-06-27
Lead Sponsor
Cancer Advances Inc.
Target Recruit Count
103
Registration Number
NCT03200821

Dose-ranging Study to Evaluate Antibody Response to G17DT in Patients With Gastric Cancer

Phase 2
Completed
Conditions
Gastric Cancer
Interventions
Drug: G17DT
First Posted Date
2015-08-13
Last Posted Date
2015-08-13
Lead Sponsor
Cancer Advances Inc.
Target Recruit Count
52
Registration Number
NCT02521649

Study to Assess Tolerability and Safety and Antibody Response to G17DT in Gastric Cancer Patients

Phase 2
Completed
Conditions
Gastric Cancer
Interventions
Biological: G17DT
First Posted Date
2015-08-10
Last Posted Date
2015-08-10
Lead Sponsor
Cancer Advances Inc.
Target Recruit Count
41
Registration Number
NCT02518529

Effect of G17DT in Patients With Stage II/III Colorectal Cancer

Phase 2
Completed
Conditions
Colorectal Cancer
Interventions
Biological: G17DT
Drug: Omeprazole
First Posted Date
2015-08-07
Last Posted Date
2015-08-07
Lead Sponsor
Cancer Advances Inc.
Target Recruit Count
22
Registration Number
NCT02518373

Study to Determine the Antibody Response to 500µg G17DT in Treatment of Patients With Gastric Cancer

Phase 2
Completed
Conditions
Gastric Cancer
Interventions
Biological: G17DT
First Posted Date
2015-05-21
Last Posted Date
2015-05-21
Lead Sponsor
Cancer Advances Inc.
Target Recruit Count
12
Registration Number
NCT02450032
Locations
🇬🇧

Glasgow Royal Infirmary, Glasgow, United Kingdom

Open-label, Dose-finding Study to Determine Antibody Response to G17DT Treatment in Patients With Gastric Cancer.

Phase 2
Completed
Conditions
Gastric Cancer
Interventions
Biological: G17DT
First Posted Date
2014-09-08
Last Posted Date
2014-09-08
Lead Sponsor
Cancer Advances Inc.
Target Recruit Count
33
Registration Number
NCT02233712

A Study of the Safety and Tolerance of Three Doses of G17DT in Metastatic Colorectal Cancer

Phase 2
Terminated
Conditions
Colorectal Cancer
Interventions
Biological: G17DT
First Posted Date
2014-08-29
Last Posted Date
2014-08-29
Lead Sponsor
Cancer Advances Inc.
Target Recruit Count
5
Registration Number
NCT02228785

Two Center Study to Determine Effect of G17DT on Plasma Gastrin Levels in Patients With Colorectal Cancer.

First Posted Date
2014-08-22
Last Posted Date
2017-06-20
Lead Sponsor
Cancer Advances Inc.
Registration Number
NCT02223078
Locations
🇬🇧

University Hospital Aintree, Liverpool, Merseyside, United Kingdom

Study to Assess Safety and Tolerability of G17DT in Patients With Colorectal Adenocarcinoma.

Phase 2
Completed
Conditions
Colorectal Cancer
Interventions
Biological: G17DT
First Posted Date
2014-07-04
Last Posted Date
2014-07-04
Lead Sponsor
Cancer Advances Inc.
Target Recruit Count
11
Registration Number
NCT02181465
Locations
🇬🇧

University Hospital, Queen's Medical Centre, Nottingham, Nottinghamshire, United Kingdom

Phase II Study to Evaluate G17DT in Combination With Irinotecan in Patients With Colorectal Carcinoma

Phase 2
Completed
Conditions
Colorectal Cancer
Interventions
Biological: G17DT-Irinotecan
First Posted Date
2014-04-21
Last Posted Date
2014-04-21
Lead Sponsor
Cancer Advances Inc.
Target Recruit Count
161
Registration Number
NCT02118064
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy